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Abstract
Hepatocellular carcinoma (HCC) is the fifth most 
common tumor in the world and the incidence is expected 
to increase in the future due to hepatitis viral infections 
and increasing cirrhosis incidence. The diagnosis of HCC 
is no longer based on biopsy especially in cases when 
curative treatment is possible. The imaging criteria are 
usually based on the vascular findings of HCC (e.g. early 
arterial uptake followed by washout in the portovenous and 
equilibrium phase). However, there are several limitations 
of the assessment of HCC by using only the vascular 
criteria. The use of tissue-specific contrast agents, including 
superparamagnetic iron oxides and hepatobiliary contrast 
agents, improves lesion detection and characterization. 
Therefore, an accurate diagnosis of HCC implies, at this 
moment, a combination of vascular and cellular information. 
This review focuses on the most important findings provided 
by the unenhanced and dynamic-enhanced CT and MR 
images regarding HCC evaluation. We also discuss the 
various imaging characteristics of HCC at MR imaging after 
the administration of tissue specific contrast agents.
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Introduction
Hepatocellular carcinoma (HCC) is the fifth most 
common tumor in the world and its incidence is expected 
to increase in the future due to hepatitis viral infections 
and increased cirrhosis incidence [1, 2]. The diagnosis of 
HCC is no longer based on biopsy especially in the cases 
when curative treatment is possible. Approximately 30% 
of patients are candidates for curative treatments including 
liver transplantation, liver resection, and percutaneous 
interventions [1] with a 5-year survival rate between 40% 
and 75% [3]. Therefore, there is an increased expectation 
from radiologists in diagnosing HCC in early stages. The 
screening for HCC includes the alpha-fetoprotein level and 
ultrasonography. However, the sensitivity of ultrasound for 
HCC detection is low since small nodules can be missed in 
a cirrhotic liver. Computed tomography (CT) and magnetic 
resonance imaging (MRI) have a high sensitivity (55%-
91%) and specificity (77%-96%) in diagnosing HCC [4]. 
According to the European Association for the Study of 
the Liver (EASL) and the American Association for the 
Study of Liver Diseases (AASLD) [5] a nodule larger than 
2 cm that displays a typical vascular pattern on contrast-
enhanced CT or contrast-enhanced MRI can be considered 
HCC without biopsy. For nodules measuring between 1 
and 2 cm, the diagnosis of HCC without biopsy requires a 
confirmation of the typical vascular pattern on both imaging 
modalities. In comparison with EASL and AASLD criteria, 
the consensus statement from the Asian Oncology Summit 
from 2009 [6] recommends that for any nodule, regardless 
of size, the characteristic features on contrast-enhanced CT 
or contrast-enhanced MRI will suffice for a diagnosis of 
HCC, and obviates the need for biopsy.
The imaging criteria used in these recommendations 
are based exclusively on the vascular findings of HCC 
after extracellular contrast agents’ administration. A typical 
enhancement is defined as an early arterial uptake followed 
by washout in the portovenous or late, equilibrium phase. 
Moreover, the evaluation of the morphological appearance 
on unenhanced images together with the evaluation of the 
vascular features on dynamic contrast-enhanced images 
enables the radiologist to provide additional information 
regarding the biomolecular angiogenetic activities in HCCs 
[7]. On the other hand, there are several limitations to the 
assessment of HCC using only the vascular criteria. The 
enhancement pattern of small HCC depends on size and 
cellular differentiation and HCCs smaller than 2 cm may 
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have atypical enhancement. Moreover, the diagnosis of HCC 
based on vascular pattern may overlook the hypovascular 
tumors. Conversely, 52% of small early arterial-enhancing 
lesions decrease in time and can be considered pseudolesions 
[8]. The use of tissue-specific contrast agents, including 
superparamagnetic iron oxides and hepatobiliary contrast 
agents, improves lesion detection and characterization due 
to additional cellular information regarding liver tumors 
including HCC. Therefore, an accurate diagnosis of HCC 
implies, at this moment, a combination of both, vascular and 
cellular, information.
This article focuses on the most important findings 
provided by unenhanced and dynamic-enhanced CT 
and MR images regarding HCC evaluation. The various 
imaging characteristics of HCC at MR imaging after the 
administration of tissue specific contrast agents are also 
discussed.
unenhanced and dynamic-enhanced Ct 
and MR imaging
Imaging findings and diagnosis performance
Dynamic contrast-enhanced CT and MRI are widely 
used for HCC diagnosis and staging. The standard protocol 
consists of acquisition during separate breath-holds of 
unenhanced images followed by acquisition of arterial, porto-
venous, and equilibrium or late phase. MRI is superior to CT 
in providing structural information on unenhanced images. 
Different MRI sequences are used to obtain information 
regarding the liver parenchyma and lesion morphology. 
The common description on unenhanced MR images refers 
to HCC as a hypointense lesion on T1-weighted images 
and hyperintense lesion on T2-weighted images compared 
to liver parenchyma [9-11]. However, several studies have 
shown that a more variable appearance of HCC is relatively 
common [12-14]. Up to 30% of HCC nodules can be 
isointense on T2-weighted images and 12% to 50% can 
display hyperintense signal on T1-weighted images [12, 
13]. These signal intensity variations on unenhanced images 
are explained by the presence, in different proportions, of 
fat, copper, iron, protein, and glycogen within the nodules 
[15, 16].
Diffusion-weighted MRI has been recently proposed as 
an additional unenhanced MRI sequence for the evaluation 
of HCC. Diffusion-weighted MRI is very sensitive to 
the motion of water protons at the microscopic level in 
response to thermal energy. Liver tumors appear as high 
signal intensity lesions in contrast to the low signal intensity 
of the liver parenchyma [17]. However, the qualitative 
analysis of the signal intensity on diffusion-weighted images 
does not enable the differentiation between malignant and 
benign lesions. A more accurate characterization of focal 
liver lesions implies a quantitative assessment based on 
the apparent diffusion coefficient (ADC). By using this 
quantitative criteria malignant lesions can be differentiated 
from benign liver lesions based on the lower ADC values 
on diffusion-weighted images [18, 19]. Several authors 
[20, 21] have demonstrated that diffusion-weighted MRI 
enables a better detection of small metastases in contrast 
with unenhanced T2-weighted images. Another study [17] 
has shown that the addition of diffusion-weighted imaging 
to the routine liver MRI in patients with cancer increases the 
number of the detected metastases with 40%. However, in 
patients with cirrhosis, HCC may be difficult to differentiate 
from dysplastic nodules or even from surrounding fibrotic 
parenchyma [18, 22-24]. A recent study showed that 
diffusion-weighted imaging has a lower sensitivity (60.7%) 
for the detection of local HCC recurrence after transarterial 
chemoembolization (TACE) compared to contrast-enhanced 
imaging (82%) [25]. In our department, diffusion-weighted 
MR imaging is part of the routine liver protocol in all 
patients. We consider that the diffusion images help to 
detect suspicious small areas within the liver. However, 
the diffusion images should be interpreted in conjunction 
with T1 and T2-weighted unenhanced images and contrast-
enhanced images [26]. 
The dynamic-enhanced acquisitions after the 
administration of extracellular contrast agents help to 
detect and further characterize HCC. The extracellular 
contrast agents distribute from the intravascular space into 
the interstitial space. A typical enhancement is defined as an 
early arterial uptake followed by washout in the portovenous 
or delayed phases. Regardless of the imaging technique, 
the enhancement pattern depends on several morphological 
characteristics of the lesion, such as vascularity, and leakiness 
of the vascular endothelial cells [27]. The arterial phase is the 
most important set of images. HCC is by definition a tumor 
with high arterial vascularization. During the arterial phase 
the HCC nodule displays a strong contrast uptake in contrast 
with the low enhancement of the liver parenchyma (Fig. 
1). The liver parenchyma enhances progressively having 
the maximum uptake in the portovenous and equilibrium 
phases. During these phases, HCC displays a wash-out of the 
contrast agent. In Table I, different studies are presented in 
which the performance of dynamic-enhanced CT and MRI 
in diagnosing HCC has been verified against histological 
findings as a standard of reference. The wide range of 
the sensitivity for both techniques may be explained by 
differences in patient selection, differences of the contrast 
agents properties or by variations in the imaging protocol. 
Pooled estimates of sensitivities of dynamic-enhanced CT 
and MR imaging for the detection of HCC are 37% and 
55%, respectively [28, 29]. The diagnosis of small HCCs is 
particularly difficult because they have to be differentiated 
from regenerative nodules, from small hemangiomas, 
or from arterioportal shunts. All of these benign lesions 
can display strong arterial uptake. Shimizu et al [8] have 
demonstrated that a significant percentage of the small early 
arterial enhancing lesions in patients with cirrhosis or chronic 
hepatitis are not HCCs. From 104 small arterial-enhancing 
lesions (< 20 mm) that were round or oval in shape only 
28% were classified as HCC based on their interval growth 
or pathologic confirmation. More than half of the lesions 
(52%) were considered definitely not HCC and 20% of the 
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lesions were stable in size and appearance and they were 
considered probably pseudolesions. Moreover, in their study, 
48% of the small HCCs were only detected in the arterial 
phase and these nodules did not display the typical wash-out 
pattern in the portal and delayed phases.
The low sensitivity of dynamic-enhanced CT and MRI 
in diagnosing small nodules of HCC is explained also by 
the difficulty in the detection and characterization of the 
nodules with atypical enhancement. Several studies [27, 
30-32] have demonstrated that 27% to 34% of the small 
HCCs are hypovascular. Therefore, the actual criteria based 
only on the “typical” vascular enhancement pattern should 
be reconsidered especially in the cases of HCCs smaller 
than 20 mm.
Correlations of the Ct and MRI findings with the 
biomolecular angiogenetic activities
Recently, the predictions of tumor growth and the 
relations between imaging findings and biomolecular 
angiogenetic activities in HCC have been investigated 
[33-36]. Investigations of these relationships may help 
radiologists to understand findings related to molecular 
biologic treatments. The vascular endothelial growth factor 
Fig 1. Two HCC nodules in a 58-year-old cirrhotic 
man. Dynamic-enhanced CT. (a) Axial unenhanced 
CT image demonstrates a well delineated 
inhomogenenous nodule in the left lobe (arrow). 
(b) On an arterial-enhanced CT image the nodule 
evidences an inhomogeneous enhancement (arrow). 
Another adjacent hypervascularized nodule is 
detected (small arrow).
(VEGF) is a heparin-binding glycoprotein that is secreted 
as a homodimer of 45 kd [37]. Solid tumors are composed 
from vascular and connective stroma and the malignant cells 
which are dispersed between stroma. The connective tissue 
provides the vascular supply of the tumor. VEGF plays an 
important role in regulating angiogenesis, endothelial cell 
proliferation, and hyperpermeability, and is responsible for 
the fibrin deposition in tumor [38]. In a study of Suzuki et 
al [34], it was demonstrated that VEGF is overexpressed in 
HCC compared with the nontumoral part of the liver. Several 
studies [34-36, 39] have shown that theVEGF expression in 
HCC is correlated with several imaging findings. Thus, the 
more heterogeneous signal intensity of HCC is the stronger 
VEGF expression of HCC [7]. Heterogeneity of HCC on 
unenhanced and contrast-enhanced CT and MRI is the result 
of an uneven distribution of extracellular free water, the 
presence of fibrosis, fat, and intratumoral necrosis [7]. Rapid 
cell proliferation in the center of a tumor leads to increased 
interstitial pressure, which may further lead to compression 
of vessels, hypoxia, and intratumoral necrosis. An inefficient 
vascular supply with concomitant hypoxia determines tumor 
neovascularization to satisfy the needs of tissue [34, 39]. The 
nonparenchymal and parenchymal hypoxic regions of solid 
tumors produce powerful and directly angiogenic proteins 
such as VEGF [39]. Therefore the VEGF expression in the 
tumor cells seems to be elevated in areas adjacent to tumor 
necrosis [7, 34]. The presence of fat within HCC is another 
cause of signal heterogeneity on CT and MR images. It has 
been shown that hypoxia induces also a higher content of 
fat within the endothelial cells [40].
Some authors have found a correlation between the 
VEGF expression and stroma formation [34, 41]. Tumor cells 
are not known to synthesize fibrinogen. VEGF transcript 
expression is thought to be responsible for fibrin deposition 
in the tumor as a result of vascular hyperpermeability [38]. 
Suzuki et al [34] have demonstrated a statistically significant 
correlation between VEGF expression and fibrous capsule 
and septal formation of the tumor. However, it seems that the 
distribution of fibrotic changes may be determined by VEGF 
receptors expression, not by VEGF expression [34]. 
There is data [36] that suggests that VEGF may 
be a pathophysiological factor that regulates contrast 
enhancement on dynamic contrast-enhanced imaging 
studies, and that the expression of VEGF may be estimated 
with MRI and CT. However, there are controversial reports 
regarding the correlation between the arterial enhancement 
of HCC and VEGF expression. Some authors reported that 
VEGF activity is not correlated with the vascularity of HCCs 
as determined by conventional angiography [33, 34]. Other 
authors have reported that VEGF activity correlates directly 
with the intensity of tumor enhancement on angiography 
[42]. Kanematsu et al [35] evaluated 20 HCC nodules 
by using CT angiography and they compared the arterial 
enhancement with the intensity of VEGF expression in HCC 
and the surrounding parenchyma. Their results indicated 
that the more hypervascular an HCC is on CT arterial phase 
images, the weaker the VEGF expression in the tumor is. 
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The authors suggested that an increased VEGF expression 
is present only in HCCs that are hypovascular in arterial 
phase. A possible cause of the decrease activity of VEGF 
in hypervascular HCCs is represented by the fact that there 
is an upregulation of VEGF that leads to gene suppression 
once a hypervascular HCC has been developed. According to 
another study [7], there is an inverse correlation between the 
enhancement intensity of HCCs in the arterial phase on MR 
images and VEGF activity of the HCC compared to VEGF 
of the surrounding liver. These results also suggest that the 
hypervascular HCCs have a low VEGF activity. However, 
Kwak et al [36] showed that the degree of VEGF expression 
is directly correlated with the degree of contrast enhancement 
on arterial-enhanced CT images. The authors suggested 
that the strong arterial enhancement of HCC is the result 
of a strong VEGF expression which is responsible for an 
increased vascular permeability and increased proliferation 
of the endothelial cells. Further studies are needed to clarify 
the correlation between the hypo- and hypervascular HCCs 
in the arterial phase and the expression of VEGF. This 
correlation may be an important observation when deciding 
to use the recently developed antiangiogenic tumor therapy 
involving the use of monoclonal antibody against VEGF.
tissue specific contrast-enhanced MR imaging
The enhancement patterns at CT and MRI during the 
different vascular phases after extracellular contrast agents 
administration is an important tool in the detection and 
characterization of HCC because many of these lesions are 
occult on unenhanced images. However, there is general 
agreement that the diagnostic performance of HCC on 
dynamic contrast enhanced CT and MR imaging depends 
on the tumor size with sensitivity and specificity values 
significantly higher for lesions larger than 20 mm in diameter 
compared with those smaller than 20 mm. The tissue specific 
contrast agents were introduced in order to improve the 
diagnostic accuracy of the liver lesions by targeting different 
cellular component of the focal liver lesions, such as Kupffer 
cells or hepatocytes. There are two different types of tissue 
specific contrast agents that can be used in clinical practice: 
reticuloendothelial and hepatobiliary contrast agents. By 
table I. The reported sensitivities and specificities of dynamic-enhanced CT and MRI with extracellular contrast agents 
in diagnosing HCC against histological findings as a standard of reference.
Author/year Imaging technique HCC mean diameter (mm) Sensitivity 
(%)
Specificity 
(%)
Lim et al / 2000 [83] Dynamic CT 19 71
Krinsky et al / 2001 [28] Dynamic MRI 18 55
Tomemori et al / 2001 [82] Dynamic CT < 20 67.6
Dynamic CT < 20 85.3
Rode et al / 2001 [72] Dynamic CT > 8 53.8
Dynamic MRI > 8 76.9
Krinsky et al / 2002 [81] Dynamic MRI > 20 100
10-20 52
< 10 4
Burrel et al / 2003 [73] MR angiography 29 mm for main nodules and 
11 mm for additional nodules
76
Dynamic CT 61
Brancatelli et al / 2003 [80] Dynamic CT 60.8 52
Valls et al / 2004 [74] Dynamic CT > 20 93.6
< 20 61
Kim et al / 2005 [52] Dynamic CT > 10 91.3 95.3
< 10 29
Dynamic MRI > 10 90.2 97
29
Kim et al / 2006 [75] Dynamic CT 18 77.4 - 79.2
< 10 47.1
Ronzoni et al / 2007 [79] Dynamic CT 17 77 75
Lauenstein et al / 2007 [76] Dynamic MRI < 20 35.71
Forner et al / 2008 [78] Dynamic MRI < 20 61.7 96.6
Heilmaier et al / 2009 [27] Dynamic MRI
Marin et al / 2009 [77] Dynamic CT 23 61
Dynamic MRI 23 63
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using these contrast agents the diagnosis of HCC is based 
on a combination of different imaging features.
Reticuloendothelial contrast agents
The reticuloendothelial contrast agents are taken up by 
the reticuloendothelial cells particularly from the liver and 
spleen and reflect the number of functioning Kupffer cells 
[43]. There are two different types of contrast agents in 
clinical use and both contain iron-based particles with 30-150 
nm in diameter. They are referred to as super paramagnetic 
iron oxides (SPIO) [44]. Ferumoxides (Feridex, Advanced 
Magnetics, Cambridge, Mass; Endorem, Guerbet, Aulnay 
sous Bois, France) are administered as a slow infusion over 
30-60 minutes and the imaging is typically performed 1-4 
hours after infusion. Ferucarbotran (Resovist; Schering 
Diagnostics, Berlin, Germany) is administered in bolus and 
the imaging is performed 10-20 minutes after administration 
[27, 45-47]. SPIO are used as a negative MR contrast agent. 
Although SPIO shorten both T1 and T2 relaxation time, in 
the accumulation phase when the SPIO particles are taken up 
by the Kupffer cells, T2 and T2* effects and, less frequently 
T1 effects, are used in lesion detection and characterization. 
Their superparamagnetic properties determine a reduced 
signal intensity on T2-weighted images [43]. Tissues with 
decreased reticuloendothelial system function (i.e., the 
absence of the Kupffer cells or a low phagocytic activity of 
the Kupffer cells, such as occurs in metastases and HCC) 
retain their native signal intensity on T2-weighted images 
and become more conspicuous in contrast with the lower 
signal intensity of the normal liver parenchyma (Fig. 2). 
Several authors [48, 49] have compared the diagnostic 
performance of dynamic-enhanced MRI with extracellular 
contrast agents with SPIO-enhanced MRI for HCC. Some 
studies [48, 50] showed that SPIO-enhanced T2-weighted 
images are more accurate than unenhanced and conventional 
contrast-enhanced CT and MR images. Other studies [47, 
49, 51-55] have reported either no significant difference 
between the two modalities or slightly better performance 
of contrast-enhanced CT and MR images with extracellular 
contrast agents. However, there is substantial variability 
in the number and functionality of Kupffer cells between 
well-differentiated HCC with almost normal Kupffer cell 
function and nondifferentiated HCC with depleted Kupffer 
cells. Therefore, the use of SPIO as a single contrast agent 
is controversial [46, 48, 49, 51, 54].
The administration of SPIO in conjunction with 
extracellular contrast agents in the same patient during one 
MR imaging examination, the so-called double-contrast MR 
imaging technique, has been proposed in order to overcome 
the limitations of single-contrast MR imaging in diagnosing 
HCC [27, 56-59]. Well-differentiated HCC may show some 
uptake of superparamagnetic iron oxide, and some lesions 
may mimic the hypervascular features of HCC. Moreover, 
there are HCCs that are hypovascular and are not detected 
on dynamic-enhanced imaging. Combining the MR imaging 
criteria of HCC with both superparamagnetic iron oxide 
and extracellular contrast agent provides a more rigorous 
approach to lesion characterization (Table II). On double-
contrast MR imaging the differential diagnosis of HCC 
and other lesions (i.e. hemangiomas, arterioportal shunts, 
regenerative nodule, dysplastic nodules) is facilitated by 
the different available information: cellular and vascular. 
The disadvantages of the use of two contrast agents in one 
patient consists of the increase in the overall cost of the 
MR examination and the lengthening of the time for image 
acquisition and analysis.
Fig 2. Hepatocellular carcinoma in a 64-year-old 
cirrhotic man. MR imaging with ferucarbotran. Axial 
unenhanced T2-weighted image (a) demonstrates a 
slightly hyperintense nodule (arrow). T2-weighted 
fat-supressed image obtained 10 minutes after 
ferucarbotran administration (b) shows increased 
signal intensity compared to the surrounding liver 
parenchyma (arrow). A diagnosis of HCC was 
confirmed at histopathology.
table II. Criteria for diagnosing HCC at mono-contrast and double-
contrast MR imaging techniques [47]
MR Technique Enhancement pattern of HCC
Mono-contrast 
dynamic-enhanced with 
extracellular contrast 
agents
Hypervascular in arterial phase with wash-
out in the portovenous or late phase
Mono-contrast with  
SPIO-enhanced
Nodules hypointense on unenhaced 
T2-weighted images which display 
hyperintensity on T2-weighted images 
after SPIO administration
OR
Nodules hyperintense or isointense on 
unenhanced T2-weighted images with no 
signal reduction after SPIO administration
Double-Contrast MR 
imaging
Nodules assessed as HCC on dynamic-
enhanced MR imaging with extracellular 
contrast agents OR on SPIO-enhanced 
images
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Double-contrast MR imaging is highly sensitive for 
diagnosing HCC in patients with cirrhotic liver. For the 
detection of HCCs measuring 10-20 mm the reported 
sensitivity of double-contrast MR imaging is 92% [45, 60]. 
Several studies have compared double-contrast MR imaging 
with mono-contrast technique and showed that double-
contrast technique significantly improves the diagnosis 
of HCC [27, 58, 61, 62]. The sequential administration 
of both types of contrast agents have demonstrated their 
superiority to the mono-contrast techniques in the assessment 
of the efficacy of HCC after treatment (i.e. transarterial 
chemoembolization - TACE) [47]. With the dynamic 
gadolinium-enhanced technique, the sensitivity, specificity, 
and accuracy is 68%, 100%, and 72% respectively for 
viable tumor detection after treatment. The SPIO-enhanced 
technique is more sensitive (80%) and accurate (83%) 
compared to the extracellular contrast-enhanced technique 
(68% sensitivity and 72% accuracy), and the double-contrast 
technique is more accurate (92%) in viable tumor detection 
after TACE compared to the mono-contrast techniques 
[47]. Moreover, it has been demonstrated that the double-
contrast technique increases the diagnostic confidence of the 
radiologist in HCC diagnosis compared with SPIO-enhanced 
and dynamic-enhanced MR imaging with extracellular 
contrast agents [27]. 
Hepatobiliary contrast agents
There are two different MR imaging contrast agents with 
hepatocyte-selective properties that include the manganese-
based and the gadolinium-based [63]. Both contrast agents 
are considered positive MR imaging agents having a T1-
shortening effect. The manganese-based contrast agents 
(Mn-DPDP, GE Healthcare, Oslo, Norway) are administered 
as a slow infusion over 10-20 minutes and delayed T1-
weighted imaging can be performed 30 minutes to 4 hours 
after infusion. The gadolinium-based contrast agents (Gd-
EOB-DTPA, Bayer-Schering Pharma, Berlin, Germany and 
Gd-BOPTA, Bracco, Milan, Italy) have double properties. 
They can be administered in rapid bolus having the same 
perfusion properties as extracellular contrast agents [63]. 
After 20 minutes the contrast agent is taken up by the 
normal hepatocytes and delayed T1-weighted MR images 
are obtained. Because an important percentage of the 
contrast agent (i.e. up to 25% for Gd-Bopta and up to 50% 
for Gd-EOB-DTPA) is excreted through the bile, the biliary 
tract presents a high degree of enhancement at T1-weighted 
delayed MR images. This delayed phase is known in MR 
imaging as the hepatobiliary phase. The hepatobiliary contrast 
agents are not taken up only by normal liver parenchyma but 
also by focal liver lesions of hepatocellular origin (adenoma, 
focal nodular hyperplasia, regenerative and dysplatic 
nodules in cirrhosis, HCC). Thus, the use of these contrast 
agents particularly enables the differentiation between 
hepatocyte-containing from non-hepatocyte-containing 
lesions (metastases, hepatic cysts, hemangiomas, abscesses) 
[64]. Many authors have demonstrated that hepatobiliary 
contrast-enhanced MR imaging is superior to extracellular 
contrast-enhanced MR imaging and dynamic-enhanced CT 
in the diagnosis of metastases [65-67]. Moreover, there is 
data that shows that the total diagnostic cost for the imaging 
strategy with initial MR imaging with Gd-EOB-DTPA is 
similar to dynamic-enhanced CT as an initial diagnostic 
modality, and offers lower costs than dynamic-enhanced 
MR imaging with extracellular contrast agents in patients 
with suspected colorectal liver metastases [65]. However, 
for these patients, MR imaging with hepatobiliary contrast 
agents improves preoperative planning, and leads to cost 
savings through shorter operative time and a higher rate of 
avoidance of unnecessary procedures [65].
In HCC, the degree of enhancement in the hepatobiliary 
phase is correlated with the degree of differentiation and 
several authors have based their approach to grading HCC 
with hepatobiliary uptake in MR imaging [68-70]. The well-
differentiated HCCs take up hepatobiliary contrast agents. 
Therefore, they appear either iso- or hyperintense to liver 
parenchyma in the hepatobiliary phase. In cirrhotic patients 
HCC nodules are difficult to be differentiated from the 
isointense regenerative nodules or hyperintense premalignant 
dysplastic nodules. The moderately to poorly differentiated 
HCCs do not display hepatobiliary contrast agent uptake and 
they appear hypointense at MR imaging in the hepatobilary 
phase (Fig 3). The overall pooled sensitivity for detection 
of HCC at liver imaging with hepatobiliary contrast agents 
is 81% [71]. Some authors [71] have proposed that the use 
of hepatobiliary contrast agents in cirrhotic patients should 
be reserved for problematic cases in order to determine the 
degree of differentiation of HCC. However, the perfusion 
properties of the gadolinium-based hepatobiliary contrast 
agents enables a bimodal evaluation of HCCs based on both 
a vascular and hepatobiliary pattern (Table III). 
table III. Vascular and hepatobiliary criteria for diagnosing HCC at 
MR imaging with gadolinium-based hepatobiliary contrast agents.
Enhancement pattern of HCC
Typical vascular pattern of the 
nodule on dynamic-enhanced 
images1
Atypical vascular pattern of the 
nodule2
AND
Hypointense nodule compared to 
liver parenchyma on hepatobiliary 
phase images3
Notes
1.  A typical vascular pattern is defined as an early arterial uptake followed 
by washout in the portovenous or equilibrium phases;
2.  An atypical vascular pattern is defined as any pattern that differ from 
the typical enhancement in any of the vascular phases (ie. hypo- or -
isointense on arterial phase with no washout in later phases);
3. The hypointensity of the nodule in the hepatobiliary phase is an indicator 
of the presence of a moderately to poorly differentiated HCC.
Conclusion
The final diagnosis of HCC is increasingly based on 
imaging criteria. The evaluation of the dynamic-enhanced 
CT and MR images provides valuable information regarding 
the vascular pattern and additional information regarding 
the biomolecular angiogenetic activities in HCCs. However, 
there are several limitations of the vascular evaluation 
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of HCC. The administration of the cellular specific MR 
imaging contrast agents may overcome these limitations in 
diagnosing HCC. 
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